Ipsen

This article is about the company. For a list of people with the surname, see Ipsen (surname).

Ipsen
Company typePublic
Euronext Paris: IPN
CAC Mid 60 Component
ISINFR0010259150
IndustryPharmaceutical
Founded1929
FounderHenri Beaufour
HeadquartersBoulogne-Billancourt, France
Key people
Marc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
ProductsList of medicines
RevenueIncrease €3.128 billion(2023)[1]
Increase €1.001 billion(2023)[1]
Increase €647 million(2023)[1]
Number of employees
5,700[1]
Websitewww.ipsen.com
Footnotes / references
[1]

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.[2][3]

Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005).[4][5] The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.[6]

  1. ^ a b c d e "FY 2023 results" (PDF). Ipsen.
  2. ^ "Ipsen: A dynamic, fast-growing specialty care powerhouse".
  3. ^ "Ipsen | Evaluate".
  4. ^ "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 13 December 2022.
  5. ^ "Ipsen, le défi américain". Les Echos (in French). 1 October 2015. Retrieved 13 December 2022.
  6. ^ France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". www.lechorepublicain.fr. Retrieved 13 December 2022.